» Articles » PMID: 37638023

Customizably Designed Multibodies Neutralize SARS-CoV-2 in a Variant-insensitive Manner

Abstract

The COVID-19 pandemic evolves constantly, requiring adaptable solutions to combat emerging SARS-CoV-2 variants. To address this, we created a pentameric scaffold based on a mammalian protein, which can be customized with up to 10 protein binding modules. This molecular scaffold spans roughly 20 nm and can simultaneously neutralize SARS-CoV-2 Spike proteins from one or multiple viral particles. Using only two different modules targeting the Spike's RBD domain, this construct outcompetes human antibodies from vaccinated individuals' serum and blocks cell attachment and pseudotyped virus entry. Additionally, the multibodies inhibit viral replication at low picomolar concentrations, regardless of the variant. This customizable multibody can be easily produced in procaryote systems, providing a new avenue for therapeutic development and detection devices, and contributing to preparedness against rapidly evolving pathogens.

References
1.
Milani M, Donalisio M, Milan Bonotto R, Schneider E, Arduino I, Boni F . Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors. Antiviral Res. 2021; 189:105055. PMC: 7944860. DOI: 10.1016/j.antiviral.2021.105055. View

2.
Watson O, Barnsley G, Toor J, Hogan A, Winskill P, Ghani A . Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022; 22(9):1293-1302. PMC: 9225255. DOI: 10.1016/S1473-3099(22)00320-6. View

3.
Correa A, Ortega C, Obal G, Alzari P, Vincentelli R, Oppezzo P . Generation of a vector suite for protein solubility screening. Front Microbiol. 2014; 5:67. PMC: 3934309. DOI: 10.3389/fmicb.2014.00067. View

4.
Sun D, Sang Z, Kim Y, Xiang Y, Cohen T, Belford A . Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Nat Commun. 2021; 12(1):4676. PMC: 8333356. DOI: 10.1038/s41467-021-24963-3. View

5.
Han Y, Kral P . Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2. ACS Nano. 2020; 14(4):5143-5147. PMC: 7163933. DOI: 10.1021/acsnano.0c02857. View